Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients

The first-line therapy in metastatic renal cell carcinoma (mRCC), sunitinib, exhibits an objective response rate of approximately 30%. Therapeutic alternatives such as other tyrosine kinase inhibitors, VEGF inhibitors, or mTOR inhibitors emphasize the clinical need to predict the patient's resp...

Full description

Bibliographic Details

Published in:	Translational Oncology
Main Authors:	Simon Matoori, Yeeliang Thian, Dow-Mu Koh, Aslam Sohaib, James Larkin, Lisa Pickering, Andreas Gutzeit
Format:	Article
Language:	English
Published:	Elsevier 2017-08-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523317301262